Novo Nordisk A/S's Total Assets for the quarter that ended in Dec. 2023 was $46,012 Mil.
Warning Sign:
If a company builds assets at 25% a year, faster than its revenue growth rate of 16.7% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Novo Nordisk A/S's average Total Assets Growth Rate was 30.60% per year.
During the past 3 years, the average Total Assets Growth Rate was 29.10% per year.
During the past 5 years, the average Total Assets Growth Rate was 25.00% per year.
During the past 10 years, the average Total Assets Growth Rate was 17.00% per year.
During the past 13 years, Novo Nordisk A/S's highest 3-Year average Total Assets Growth Rate was 29.10%. The lowest was -1.70%. And the median was 10.10%.
The historical data trend for Novo Nordisk A/S's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Novo Nordisk A/S's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk A/S (NYSE:NVO) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Novo Nordisk A/S's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Novo Nordisk A/S Total Assets Related Terms
Thank you for viewing the detailed overview of Novo Nordisk A/S's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Novo Nordisk A/S (Novo Nordisk A/S) Business Description
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NVO has been successfully added to your 